# Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

> **NCT02968940** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 6 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** Avelumab
- **RADIATION:** Hypofractionated radiation therapy (HFRT)

## Key facts

- **NCT ID:** NCT02968940
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-17
- **Primary completion:** 2019-08-29
- **Final completion:** 2019-08-29
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968940, "Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02968940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*